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Abstract
Background: Autism spectrum disorders (ASD) are severe neurodevelopmental disorders with the male:female ratio of 4:1,
implying the contribution of X chromosome genetic factors to the susceptibility of ASD. The ribosomal protein L10 (RPL10)
gene, located on chromosome Xq28, codes for a key protein in assembling large ribosomal subunit and protein synthesis. Two
non-synonymous mutations of RPL10, L206M and H213Q, were identified in four boys with ASD. Moreover, functional studies
of mutant RPL10 in yeast exhibited aberrant ribosomal profiles. These results provided a novel aspect of disease mechanisms
for autism – aberrant processes of ribosome biosynthesis and translation. To confirm these initial findings, we re-sequenced
RPL10 exons and quantified mRNA transcript level of RPL10 in our samples.
Methods: 141 individuals with ASD were recruited in this study. All RPL10 exons and flanking junctions were sequenced.
Furthermore, mRNA transcript level of RPL10 was quantified in B lymphoblastoid cell lines (BLCL) of 48 patients and 27 controls
using the method of SYBR Green quantitative PCR. Two sets of primer pairs were used to quantify the mRNA expression level
of RPL10: RPL10-A and RPL10-B.
Results: No non-synonymous mutations were detected in our cohort. Male controls showed similar transcript level of RPL10
compared with female controls (RPL10-A, U = 81, P = 0.7; RPL10-B, U = 61.5, P = 0.2). We did not observe any significant
difference in RPL10 transcript levels between cases and controls (RPL10-A, U = 531, P = 0.2; RPL10-B, U = 607.5, P = 0.7).
Conclusion: Our results suggest that RPL10 has no major effect on the susceptibility to ASD.
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Background
Autism spectrum disorders (ASD) are complex neurobe-
havioral disorders characterized by impaired social inter-
action and language development and by repetitive and
stereotyped behaviors and interests. Twin and family stud-
ies indicate that genetic factors contribute to the suscepti-
bility to ASD[1,2]. However, only 10–25% of cases of
autism harbour identified chromosome abnormalities
and/or present with genetic syndromes; the remaining
90% are idiopathic[3]. The male:female ratio of autism is
approximately 4:1, implying the contribution of X chro-
mosome genetic factors to the susceptibility of ASD.
Ribosomal protein L10 (RPL10), also called QM, is a
highly conserved component of the large ribosome subu-
nit (60s) that plays a crucial role in protein synthesis[4].
In humans, the RPL10 gene is located on chromosome
Xq28, within a candidate region for ASD[5]. Recently,
Klauck et al. identified two non-synonymous mutations,
L206M and H213Q, in the C-terminal domain of RPL10
in four boys with ASD from two independent families.
Furthermore, functional studies using yeast strains
expressing human mutant RPL10 cDNAs exhibited aber-
rant ribosomal profiles, suggesting that the mutations
may actually have an effect on translation[6]. High expres-
sion of RPL10 was observed in mouse hippocampus, an
important brain site for learning and memory, which are
impaired in autism[7]. To investigate whether RPL10 is
involved in the pathogenesis of autism, we sequenced all
RPL10  exons and quantified RPL10 mRNA level in
patients with ASD and controls.
Methods
Subjects
A total of 141 individuals with ASD were recruited by the
Paris Autism Research International Sibpair (PARIS)
study. All probands met DSM-IV diagnostic criteria for
autism, Asperger syndrome or pervasive developmental
disorder not otherwise specified (PDD-NOS)[8]. The
patients were evaluated by experienced psychiatrists or
child neurologists and assessed with the Autism Diagnos-
tic Interview-Revised (ADI-R) [9] or the Asperger Syn-
drome Diagnostic Interview (ASDI) [10]. Totally, 129
subjects met full criteria for autistic disorder, 6 for
Asperger Syndrome and 6 for PDD-NOS. 109 patients
showed low IQ (<70). Laboratory tests to rule out medical
causes of autism included standard karyotyping, fragile X
testing, and metabolic screening. Brain imaging and EEG
were performed when possible. Patients diagnosed with
medical disorders such as fragile X syndrome or chromo-
somal abnormalities were excluded from the study. Of
141 patients, 88 were selected from the families with X
chromosome inactivation skewing (XCI) from 289 ASD
families based on the previous study[8]. The other 53
patients were from multiplex families with random XCI.
There were 101 males and 40 females (78 subjects from
multiplex families and 63 sporadic cases). All individuals
were of European descent, except 5 sub-Saharan Africans,
and 3 of mixed ethnicity. The study was approved by the
research ethics boards of the collaborating institutions.
Informed consent was obtained from all families partici-
pating in the study.
Sequencing
All RPL10 exons and flanking junctions were amplified
using the primers described previously[6]. Amplicons
were directly sequenced using the Big Dye version 3.1 in
ABI 3100 sequencers (Applied Biosystems, Foster City,
CA)
Real-Time Quantitative PCR
A sample of 48 patients (34 males and 14 females, of
which 35 patients IQ<70) and 27 controls (15 males and
12 females, all IQ>90) were available for B lymphoblast-
oid cell lines (BLCL). Total RNA was isolated from BLCL
using the NucleoSpin®  RNA II kit. Oligo(dT)-primed
cDNA prepared from 5 μg of BLCL RNA using Superscript
II (Invitrogen, Carlsbad, CA) was used as template for
quantitative PCR with SYBR Green on an ABI PRISM 7500
instrument (Applied Biosystems, Foster City, CA). Two
sets of primer pairs were used to quantify the mRNA
expression level of RPL10: RPL10-A, spanning exons 4 and
5, and RPL10-B, spanning exons 6 and 7. The forward
primer of RPL10-A was 5'-ATA TGA GCA GCT GTC CTC
TGA AG-3' and the reverse was 5'-CCA TCT TTG CCA CAA
CTT TTT ACC-3'. The forward primer of RPL10-B was 5'-
AGA ACA AGG AGC ATG TGA TTG AG-3' and the reverse
was 5'-CTT CTT TGA GAT GTG GAT CTT CTG-3'. GAPDH
was used as an endogenous control. The forward primer
of GAPDH was 5'-GAT GAC ATC AAG AAG GTG GTG-3'
and the reverse was 5'-GTC ATA CCA GGA AAT GAG CTT
G-3'. The efficiencies of three primer sets were measured
using a dilution series of cDNA. The raw threshold cycle
(Ct) values were converted to linear form REL (relative
expression level) by the 2-ΔΔCt method to quantify the rel-
ative gene expression[11]. The REL of each transcript was
normalized to GAPDH and relative to the mean Ct value
of control males. All the reactions were performed in trip-
licate. Melting curves were analyzed for each reaction to
ensure the specificity of the amplicons.
Statistics
Statistic significance was calculated for RPL10 mRNA tran-
script levels of different groups using non parametric
Mann-Whitney U-test in SPSS10.0. The significance lever
for all statistical tests was P < 0.05.
Results
No non-synonymous mutations were detected in our
cohort. The mRNA level of RPL10 was compared in fourBMC Medical Genetics 2009, 10:7 http://www.biomedcentral.com/1471-2350/10/7
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subgroups: male controls, male ASD, female controls and
female ASD using two sets of primer pairs RPL10-A and
RPL10-B (Figure 1). In controls, the transcript level of
RPL10 was not significantly different between males and
females (RPL10-A, U = 81, P = 0.7; RPL10-B, U = 61.5, P =
0.2). When cases and controls were compared, we did not
observe any significant difference in RPL10 transcript lev-
els (RPL10-A, U = 531, P = 0.2; RPL10-B, U = 607.5, P =
0.7). Female cases had a somewhat lower expression level
of RPL10 compared with female controls (RPL10-A, U =
49, P = 0.06; RPL10-B, U = 47.5, P = 0.07). However, this
trend disappeared after correction for multiple tests.
Discussion
RPL10 belongs to the L10e family of ribosomal proteins
and is hypothesized to be necessary for ribosome assem-
Quantitative RT-PCR of RPL10 in patients with ASD and controls Figure 1
Quantitative RT-PCR of RPL10 in patients with ASD and controls. The level of RPL10 mRNA was quantified with 
two sets of primer pairs RPL10-A (a) and RPL10-B (b). Each column represents the value of relative expression level (REL) of 
an individual. The horizontal bar at 1 indicates the mean REL of male controls used as a calibrator. Four subgroups are shown 
in different colours. The REL value of each subgroup is expressed as mean ± SD.BMC Medical Genetics 2009, 10:7 http://www.biomedcentral.com/1471-2350/10/7
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bling and function. The identification of two missense
mutations in highly conserved positions of RPL10 across
species and functional studies in yeast strains expressing
human wild-type/mutant RPL10 cDNAs suggested a novel
aspect of disease mechanisms for autism – aberrant proc-
esses of ribosome biosynthesis and translation. To con-
firm these initial findings, we sequenced all RPL10 exons
and flanking junctions in 141 ASD patients. No missense
mutation was identified. We performed this study in
European population as well as Klauck et al[6] in order to
exclude the possible sample stratification. Other factors,
such as the sample size and highly genetic heterogeneity
of ASD, should be considered when explaining the
absence of RPL10 mutations in our sample. To further
address the expression issue, mRNA transcript level of
RPL10 was quantified in 48 patients and 27 controls using
the method of SYBR Green quantitative PCR. Male con-
trols showed the same transcript level of RPL10 compared
with female controls, supporting the evidence that RPL10
is subject to X chromosome inactivation [12]. No statisti-
cal significance in expression level was found between
cases and controls, suggesting there was no difference in
RPL10 expression between two groups. Taken together,
our study could not confirm the association between
RPL10 and ASD.
Three limitations should be considered in this study. First,
our sample of patients screened for RPL10 (n = 141, 101
males and 40 females) was smaller compared to the pre-
vious study (n = 345, 268 males and 77 females)[6]. We
had 56% of chance to detect at least one mutation in our
sample. Our previous study indicated XCI profile could be
a useful criteria to prioritize families for mutation screen-
ing of X-linked candidate genes in ASD, so we selected 88
individuals from the families with XCI skewing (≥ 70:30)
and 53 patients from multiplex families for mutation
screening of RPL10[8]. However, we did not detect any
functional mutations. Second, our mutation screening
was restricted to exons and therefore was not appropriate
to detect the presence of variants altering the expression of
RPL10 in promoter regions or other regulatory regions.
However, we recently performed a high-throughput geno-
typing of 91 patients from this sample using the Illumina
human1M-duo beadchip, and we could not detect any
genomic imbalance within or close to RPL10 (unpublished
data). Thirdly, we performed the quantification of RPL10
mRNA level in B lymphoblastoid cell lines and therefore
we could have missed alterations specific to brain. Thus,
further studies on other bigger samples are warranted and
the promoter regions and other regulatory regions should
be investigated.
Conclusion
The present study did not find any non-synonymous
mutations in our cohort, neither abnormal RPL10 tran-
script levels in ASD patients compared to controls, sug-
gesting that RPL10  has no major effect on the
susceptibility to ASD.
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